Raloxifene hydrochloride - Osteoporosis
You are here : Home > Formulary Search > Raloxifene hydrochloride - Osteoporosis
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Green (see narrative)
Formulations :
- Tablets
Formulary Status :
Associated Icons :
Restrictions / Comments :
Documentation
Guidelines (Local)
NICE Technology Appraisal
PAD Profile
ChemicalSubstance :
Raloxifene hydrochloride
Indication :
Osteoporosis
Group Name :
Keywords :
postmenopausal osteoporosis
Brand Names Include :
Evista
Important Information :
Only recommended as an option in secondary prevention where other options have been exhausted.
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2
Other Indications
Below are listed other indications that Raloxifene hydrochloride is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Osteoporosis.
Committee Recommendations (2)
Raloxifene is neither more efficacious or cost effective than other recommended treatments for osteoporosis and has therefore not been included within the local guidelines - available below.
Its use may be appropriate for secondary prevention in postmenopausal women if other treatment options have been exhausted
Its use may be appropriate for secondary prevention in postmenopausal women if other treatment options have been exhausted
GENERIC Raloxifene has been considered by the PCN and has been assigned a GREEN traffic light status.
NOTE - the branded product, Evista, was considered BLACK at the PCN in May 2017.
NOTE - the branded product, Evista, was considered BLACK at the PCN in May 2017.